Leah Croll, MD, Assistant Professor of Clinical Neurology at the Lewis Katz School of Medicine at Temple University, offered insight to ABC News on phase III clinical trial results for Lecanemab, a monoclonal antibody that helps remove amyloid-beta clumps. The results, published in the New England Journal of Medicine, showed the medication slowed the rate of cognitive decline in participants in the early stages of Alzheimer’s disease. Dr. Croll was not involved in the study. Yahoo! News and MSN.com picked up the ABC News article.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH